ImexpharmSTC:IMP 98 Buyback Yield % is 0.00 as of Jul. 01, 2026. GuruFocus rates STC:IMP with a GF Score™ of 98/100 and a GF Value™ of ₫51,983.47 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 293 Drug Manufacturers companies, Imexpharm ranks worse than 341296.59% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Imexpharm's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Imexpharm's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imexpharm Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Imexpharm's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Imexpharm's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imexpharm (STC:IMP) has a Buyback Yield % of 0.00 as of Jul. 01, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Imexpharm and its competitors. According to the industry distribution chart, Imexpharm ranks #999999 out of 293 companies in the Drug Manufacturers industry.
Is Imexpharm's Buyback Yield % too high?
Imexpharm's current Buyback Yield % is 0.00. Based on the distribution chart, Imexpharm ranks #999999 out of 293 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Imexpharm has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Imexpharm's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Imexpharm ranks #999999 out of 293 companies for Buyback Yield %. This places Imexpharm in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Imexpharm and its competitors. Imexpharm's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imexpharm stock overvalued right now?
Based on GuruFocus' analysis, Imexpharm (STC:IMP) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫51,983.47, compared to a current price of ₫41,200.00 — trading 20.7% below its estimated fair value. The current Buyback Yield % is 0.00. Imexpharm's overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Imexpharm (STC:IMP), the current Buyback Yield % is 0.00 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imexpharm (STC:IMP) Overvalued in 2026?
Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued.
The current stock price of ₫41,200.00 is trading 20.7% below its estimated GF Value™ of ₫51,983.47.
GuruFocus considers Imexpharm to be Modestly Undervalued.
Key valuation signals for STC:IMP:
Buyback Yield %: 0.00
GF Value™: ₫51,983.47 vs. price of ₫41,200.00 (20.7% below fair value)
No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
98GF Score
Get the complete analysis for STC:IMP
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:IMP has been successfully added to your 
